A shows the Receiver operator characteristic (ROC) curve analysis using the expression of RhoT1, Smad4 and p16 for discriminating LNM (<i>n</i> = 162).

<p>The area under the ROC curve (AUC) for RhoT1, Smad4 and p16 were 0.629, 0.551, and 0.480 respectively. B Shows the ROC curve analysis of the expression of RhoT1, Smad4 and p16 for overall survival (<i>n = </i>70). The AUC values for three proteins were 0.667, 0.643, and 0.469, respectively.</p

Clinicopathological characteristics of the pancreatic cancer.

<p>Clinicopathological characteristics of the pancreatic cancer.</p

Associations between the various clinicopathological factors and the presence of lymph node metastasis and perineural invasion.

<p>Associations between the various clinicopathological factors and the presence of lymph node metastasis and perineural invasion.</p

Panels A, B and C respectively show the negative expression of RhoT1, Smad4 and p16 in the cancer tissues.

<p>Panels D, E and F respectively show the positive expression of RhoT1, Smad4 and p16 in the paracancerous tissues. All images were taken at 200× magnification.</p

Kaplan–Meier curves showing correlation between high or low expression of RhoT1, Smad4, p16 and overall survival in patients with pancreatic cancer (<i>n = </i>70).

<p>High expression levels of RhoT1 and Smad4 correlated with better survival (<i>P</i> = 0.034, <i>P = </i>0.047, respectively; log rank test), no significant association was observed between the expression level of p16 and overall survival (<i>P</i>>0.05).</p

Univariate and multivariable Cox regression analysis of overall survival (<i>n = </i>70).

<p>Note: <i>HR</i>: Hazard ratio; LNM: lymph node metastasis; PNI: perineural Invasion.</p